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Executive summary
Background 
Over the last 10 years, biological therapies have transformed treatment for people with inflammatory 
bowel disease (IBD). Most of these drugs work by targeting a protein in the body called tumour necrosis 
factor alpha (TNFα). Overproduction of this protein is thought to be partly responsible for the chronic 
inflammation in people with IBD.  
The purpose of this audit is to measure the efficacy, safety and appropriate use of biological therapies in 
patients with IBD in the UK. The audit also aims to capture patients’ views on their quality of life at 
intervals during their treatment. This is the fifth report of the biological therapy element of the UK IBD 
audit; all analyses within this report include only those patients who were newly started on biological 
therapies between 12 September 2011 (the start of data collection) and 29 February 2016. The data 
contained within this report have only been taken from completed submissions within the biological 
therapy audit web tool (www.ibdbiologicsaudit.org). 
The biological therapies audit provides IBD teams with the means to understand whether they achieve 
Standard A6 of the IBD standards;1 specifically, regular review of patient outcomes and auditing of 
biological therapy. Participation in the audit also provides the opportunity to review compliance with 
National Institute for Health and Care Excellence (NICE) recommendations technology appraisal 1872 
and technology appraisal 3293 and also fulfils NICE quality statement 4: monitoring drug treatment in 
quality standard 81.4  
Key messages 
This round of audit is of particular interest due to the emerging availability of biosimilar infliximab 
(Inflectra and Remsima), which became available in the UK from February 2015. There is little data 
available comparing infliximab (Remicade) to its biosimilar versions (Inflectra and Remsima). The 
analysis of short-term data conducted in this report shows that infliximab biosimilars are as effective as 
infliximab (Remicade). Given that they are far less expensive than Remicade, sites should adopt 
infliximab biosimilars to take advantage of significant cost savings. This report also gives important 
insights into the use of other biological therapies adalimumab (Humira), golimumab (Simponi) and 
vedolizumab (Entivyio). 
Participation in the biological therapies audit remains consistent. Between 1 March 2015 and 29 
February 2016, 138 (87%) of the 159 eligible adult trusts / health boards and 19 (76%) of the 25 IBD 
specialist paediatric sites in the UK participated in this audit or the Personalised Anti-TNF Therapy in 
Crohn’s disease study (PANTs).5 This equates to a total of 2722 adult and 278 paediatric patients entered 
to the audit. This is the largest number of patients entered to the audit in a single year since the audit 
began in 2011. 
The data demonstrate other changes in practice with a greater proportion of patients with ulcerative 
colitis (UC) being treated, in line partly with the changes to the recommendations in NICE guidance. 
There has also been a reduction in the frequency of surgery prior to treatment and biological therapies 
being used earlier in the disease course. Data from this audit indicate that not all patients are being 
adequately screened prior to treatment. It is important that all patients are screened for opportunistic 
infections prior to starting biologics and that they are followed up appropriately to ensure the safe and 
effective use of these medicines. This report focuses primarily on new starters on biologics. However, 
continued monitoring of those patients switching to new biosimilars is also required. 
This will be the final report produced by the UK IBD audit at the Royal College of Physicians (RCP). It is 
currently in the process of transitioning data collection to support audit and quality improvement to the 
IBD Registry. It is vitally important that sites continue to monitor and audit their patients on biologics 
locally and submit data to the IBD Registry for future national comparisons where possible. 
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Key findings 
• Biological therapies are safe. Ten per cent of adult and 5% of paediatric patients audited over
the last year experienced an adverse reaction at 3-month follow-up. The commonest adverse
reaction was a rash; 3% in adult patients, 2% in paediatric patients, with infection seen in only
1% of adults. There were no reported malignancies. (Adults – Section 2, p 23 / Paediatrics – Section
3, p 38)
• Treatment rates for ulcerative colitis have increased substantially in the past year. In 2015,
ulcerative colitis represented 17% (412/2396) of adult patients and 12% (32/277) of paediatric
patients treated. This rose to 33% (903/2722) of adult patients and 17% (47/278) of paediatric
patients in 2016. (Adults – Section 2, p 21 / Paediatrics – Section 3, p 37)
• The short-term efficacy of biosimilar infliximab (Inflectra and Remsima) is equivalent to
Remicade. A response was seen at 3 months in 84% of adult and 86% of paediatric patients
treated with Inflectra/Remsima and 85% of adult and paediatric patients treated with Remicade.
(Adults – Section 2, p 26 / Paediatrics – Section 3, p 41)
• Biological treatments are being used earlier in the disease course in adult patients. The median
time from diagnosis to treatment for adult patients has fallen from 4.5 years in 2012 to 3.8 years
in 2016 (p=0.026). It has also fallen for paediatric patients from 1.2 years in 2012 to 0.9 years in
2016. (Adults – Section 2, p 21 / Paediatrics – Section 3, p 37)
• Only 60% of adult and 47% of paediatric patients audited in 2016 had complete pre-treatment
screening for opportunistic infections. For example, 82% of adult and 81% of paediatric patients
had either a Gamma interferon or Mantoux screen. (Adults – Section 2, p 19 / Paediatrics – Section
3, p 35)
• Only 31% of adult and 44% of paediatric patients audited in 2016 were recorded as having been
followed up within 3 months of initial treatment. (For the follow-up time point, a 1-month
window either side was used in order to best capture patients – eg for 3-month follow-up, data
entered 61–121 days after initial treatment were included.) (Adults – Section 2, p 18 / Paediatrics –
Section 3, p 34)
• The frequency of surgery prior to treatment has diminished over the rounds of this audit.
Surgery recorded in 2012 was 36% for adult and 25% for paediatric patients, by 2016 this had
reduced to 15% for adult and 8% for paediatric patients. In addition, surgery in the 6 months
following treatment is less frequent than in the 6 months before treatment. (Adults – Section 2, p
21 / Paediatrics – Section 3, p 37)
• It is of some concern that treatment with concomitant steroids for adult patients has increased
over the rounds of audit, rising from 28% in 2012 to 36% in 2016 at initial treatment. This use
does, however, reduce by 3-month follow-up to 7% in 2012 and 21% in 2016. (Adults – Section 2,
p 21 / Paediatrics – Section 3, p 37)
• Data from research studies can successfully be used for clinical audit purposes. The completion
of the Personalised Anti-TNF Therapy in Crohn’s disease study (PANTs) represents one of the
largest anti-TNFα research studies performed and the data have been successfully incorporated
into the biological therapies audit. (Section 1, p 15)
10 
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Recommendations 
• Clinicians should use infliximab biosimilars as the first line anti-TNFα for appropriate patients
with active IBD.
• Clinicians should completely screen all patients prior to treatment with biological therapies.
Adult patients must have a chest X-ray and screening for TB (Gamma interferon or a Mantoux
screen), as well as hepatitis B, hepatitis C and HIV. Paediatric patients must have a chest X-ray
and screening for hepatitis B and TB (Gamma interferon or a Mantoux screen).
• Clinicians should document follow-up in all patients within 3 months and at 1 year following
initial treatment with biologics. A disease activity index should also be recorded in all patients
at baseline, 3 months and 1 year as a minimum. These steps will ensure that only appropriately
responding patients continue to have treatment.
• Steroid use in all patients should be kept to a minimum. Infliximab has a steroid sparing effect
and steroids should be stopped at the first opportunity.
• Clinicians should audit all patients on biological therapies to ensure their safe and appropriate
use. Data can also be provided to studies such as PANTs5 for research. The UK IBD Registry can
be used as a mechanism to keep a register of this information, comparing local to national
outcomes and supporting audit and quality improvement (www.ibdregistry.org.uk).
• Clinicians should share findings and recommendations of this report at relevant
multidisciplinary team, clinical governance and audit meetings, with the aim of developing a
local action plan for implementing improvement.
11 
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1: Introduction and methods 
Introduction 
Biological therapies have revolutionised the treatment of inflammatory bowel disease (IBD), with usage 
increasing rapidly in the UK over the past few years. They are effective treatments and relatively safe, 
however, they remain a significant cost burden for hospitals in the UK. The availability of biosimilar 
infliximab provides an opportunity for substantial cost savings, reducing the cost of treatment from 
approximately £10,000 per patient per year to less than £5,000. However, IBD data confirming 
equivalent efficacy of infliximab biosimilars compared with Remicade are currently relatively sparse. 
Golimumab and vedolizumab have seen more widespread use in 2016 and have been included in the 
biologics audit for the first time this year. Thus continued auditing of their effectiveness, safety and 
appropriateness remains a clinical priority. Further information about biological therapies and their 
licensing can be found in section 5, pp 38–39. 
Aims of the biological therapies audit 
To assess nationally: 
1 the appropriate use/prescribing of biological therapies in the treatment of IBD 
2 the efficacy of biological therapies in the treatment of IBD 
3 the safety of biological therapies in the treatment of IBD 
4 the views of patients with IBD on their quality of life at defined intervals throughout their use of 
biological therapies. 
Methods 
This is a prospective audit, with data collection taking place in ‘real time’ during the clinical appointment 
with the patient. Participating sites are asked to identify and enter data on patients newly started on 
biological therapies. Data entry takes place in the form of ‘submissions’ to a web-based data collection 
tool (www.ibdbiologicsaudit.org). A submission refers to data entered in any of the following 
categories: patient demographics, IBD disease details, initial anti-TNFα treatment, follow-up anti-TNFα 
treatment and IBD-related surgery. Further detail about each of the categories can be found in section 
6, pp 40–43 of this report. 
Definition of a ‘site’ 
Lead clinicians are asked to collect and submit data on the basis of a unified IBD service that would be 
registered as a named ‘site’. This is typically a single hospital within a trust / health board, but where 
more than one hospital under a trust / health board offers independent IBD services, data are entered 
for separate ‘sites’. Some organisations that run a coordinated IBD service across several hospitals with 
the same staff participate in the audit as one trust / health board-wide site. 
Eligibility and participation 
Sites are eligible to participate in the biological therapies audit if they prescribe and administer 
biological therapy to their patients with IBD. Of the 159 adult trusts / health boards eligible to 
participate in the UK, 138 are participating in the biological therapies element and/or in the 
Personalised Anti-TNF Therapy in Crohn’s disease study (PANTs)5 as well as 19 of the 25 specialist 
paediatric IBD sites; see below for further information. There are a further eight paediatric sites 
participating in addition to the specialist ones (27 in total). Paediatric patients may also be receiving 
biological therapies under adult gastroenterology services. Further information on participation and a 
list of participating and non-participating sites can be found in section 7, pp 53–79 of this report. 
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PANTs 
The PANTS5 study started in March 2013 and finished patient recruitment in July 2016 with follow-up 
data still being collected. It is a prospective, uncontrolled, cohort study investigating primary non-
response, loss of response and adverse drug reactions to infliximab and adalimumab in patients with 
severe active luminal Crohn’s disease (CD). The collected clinical data are aligned with data collected by 
the biological therapy audit (and in due course with the UK IBD registry). Relevant anonymised data 
from PANTs have been included and analysed in this report. Sites submitting data to PANTs are 
indicated by an asterisk in the list of participating and non-participating sites in section 7, pp 53–79 of 
this report. 
Inclusion and exclusion criteria 
Only patients with diagnosed IBD – that is, CD, ulcerative colitis (UC) and IBD unclassified (IBDU) – who 
have been started on biological therapy for the treatment of their IBD are included. Patients of all ages 
are included in the audit. Sites that do not provide any biological treatment to their patients with IBD 
are excluded from participation. The process of including and excluding data in national analyses is 
detailed in the initial treatment consort diagrams on p 17 for adult patients and p 33 for paediatric 
patients in this report. 
Denominators 
Denominators throughout the report vary depending on the number of submissions to which the 
analysed data relate. A submission refers to data entered in any of the following categories: patient 
demographics, IBD disease details, initial treatment, follow-up treatment and IBD-related surgery. For 
example, a single patient can have multiple initial or follow-up treatments and may have been treated 
with one or both drug types. The denominators can vary considerably, so readers should review all table 
notes and explanatory text provided within the report. 
Data-collection tool 
The web-based data collection tool was developed by Westcliff Solutions Ltd: 
www.westcliffsolutions.co.uk. Security and confidentiality are maintained during data collection by 
using unique usernames and passwords; only the lead clinician at each site can authorise local access. 
Data can be saved during and at the end of an input session, and online help – including definitions and 
clarifications of data items, internal logical data checks and instant feedback mechanisms – ensure that 
high-quality data are collected. For an explanation of the different submission types in the biological 
therapies audit, please see section 6, pp 49–52 of this report. 
Site-level data 
The IBD programme steering group, having taken statistical advice, has identified a sample size of fewer 
than six patients as potentially compromising patient anonymity. Results in site reports that meet this 
criterion have therefore been replaced with ‘n<6’.  
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Evidence 
Guidance referred to within this report is taken from the following sources: 
• IBD Standards Group, 2013. Standards for the healthcare of people who have inflammatory
bowel disease, IBD standards, 2013 update. www.ibdstandards.org.uk [Accessed 16 July 2015]. 
• Mowat C, Cole A, Windsor A et al, on behalf of the IBD Section of the British Society of
Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 
2011;60:571–607.  
• National Institute for Health and Care Excellence, 2008. Technology appraisal 163: Infliximab for
acute exacerbations of ulcerative colitis. www.nice.org.uk/guidance/TA163. [Accessed 16 July 
2015]. 
• National Institute for Health and Care Excellence, 2011. Technology appraisal 187: Infliximab
(review) and adalimumab for the treatment of Crohn’s disease. 
www.nice.org.uk/guidance/TA187 [Accessed 16 July 2015]. 
• National Institute for Health and Care Excellence, 2015. Technology appraisal 329: Infliximab,
adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the 
failure of conventional therapy (including a review of TA140 and TA262). 
www.nice.org.uk/guidance/TA329 [Accessed 16 July 2015]. 
• National Institute for Health and Care Excellence, 2015. Quality standard 81: Inflammatory
bowel disease. www.nice.org.uk/guidance/QS81 [Accessed 16 July 2015]. 
• Royal College of Physicians, 2014. Experience of inpatients with ulcerative colitis throughout the
UK. 
• Royal College of Physicians, 2014. National clinical audit of inpatient care for adults with
ulcerative colitis. 
Availability of audit results in the public domain
Full and executive summary copies of this report are available in the public domain via the Royal College 
of Physicians (RCP) website (www.rcplondon.ac.uk/biologics). The national report of results will be 
made available to NHS England; the Department of Health, Social Services and Public Safety in Northern 
Ireland; Healthcare Improvement Scotland; and the Department for Health and Social Services in Wales. 
A number of key indicators for each of the participating sites are published in the public domain in 
section 7, pp 54–79 of this report; these findings are also available via www.data.gov.uk, in line with 
the government’s transparency agenda. 
Presentation of results 
National results are presented as percentages for categorical data and as medians and interquartile 
ranges (IQRs) for numerical data. This report summarises data provided by sites that registered to 
participate in the audit and indicated that they provide their IBD service to adult patients or paediatric 
patients. Full national data results for both adult and paediatric patients can be found in online 
appendices 5 and 6 at www.rcplondon.ac.uk/biologics. 
16 
© Healthcare Quality Improvement Partnership 2016 
National clinical audit of biological therapies. Annual report. September 2016. UK IBD audit 
2: Key results – adult services 
Consort diagram for initial treatment – adult patients  
Between 1 March 2015 and 29 February 2016, 2722 individual adult patient demographic submissions 
had been entered on the web tool.  
Fig 1 Consort diagram for initial treatment – adult patients 
CD = Crohn’s disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative colitis. 
Fig 1 is integral to understanding the patient numbers and the reasons that patients were excluded from 
analysis when considering the results in this report. Readers are reminded that individual results are 
often a subset of this number and that the context and actual number of cases should be considered 
when interpreting findings. A consort diagram detailing patient numbers and reasons for exclusion from 
follow-up treatment data can be found in Appendix 3, p 83.
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Understanding these results 
The tables in this section use key data items to address the objectives of the biological therapies audit 
and provide an overall view of the main characteristics of the included patients. It is important to note 
that this report is patient focused rather than treatment based. All analysis in this section relates to data 
entered to the audit between 1 March 2015 and 29 February 2016, apart from Table 5 which includes 
over time analysis. 
The results in this section should not be directly compared with any previous biological therapy audit 
report. This is due to sites being able to lock and unlock any case entered to the audit since its 
inception and amend data retrospectively.  
The consort diagram in Fig 1 (p 9) shows that only those patients with at least one initial treatment were 
included in the analyses. Thereafter, the numbers reduce based on whether patients were recorded as 
having been followed up at 3 and 12 months after initial treatment. For the follow-up time point, a 1-
month window either side was used in order to best capture patients – eg for 3-month follow-up, data 
entered 60–120 days after initial treatment were included. 
Table 1 Adult patient summary 
This table provides a summary of adult patients and their treatments included in the national analysis. 
Patient group, % (n) 
Treatment and biologic type CD UC IBDU All IBD 
Initial treatment (n=1766) (n=903) (n=53) (n=2722) 
Golimumab (Simponi) 0.1% (2) 7% (62) - 2% (64) 
Adalimumab (Humira) 50% (888) 27% (247) 36% (19) 42% (1154) 
Infliximab biosimilar (Inflectra/Remsima) 20% (354) 25% (228) 26% (14) 22% (596) 
Infliximab (Remicade) 28% (491) 32% (292) 32% (17) 29% (800) 
Vedolizumab (Entyvio) 2% (31) 8% (74) 6% (3) 4% (108) 
3-month follow-up (n=591) (n=247) (n=17) (n=855) 
Golimumab (Simponi) 0.2% (1) 9% (22) - 3% (23) 
Adalimumab (Humira) 46% (273) 26% (64) 35% (6) 40% (343) 
Infliximab biosimilar (Inflectra/Remsima) 17% (99) 19% (48) 35% (6) 18% (153) 
Infliximab (Remicade) 35% (208) 37% (92) 29% (5) 36% (305) 
Vedolizumab (Entyvio) 2% (10) 9% (21) - 4% (31) 
12-month follow-up (n=5) (n=1) (n=0) (n=6) 
Golimumab (Simponi) - - - - 
Adalimumab (Humira) 60% (3) - - 50% (3) 
Infliximab biosimilar (Inflectra/Remsima) - - - - 
Infliximab (Remicade) 40% (2) 100% (1) - 50% (3) 
Vedolizumab (Entyvio) - - - - 
CD = Crohn’s disease; IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative 
colitis. 
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Table 2 Key demographic items data – adult patients 
Table 2 compares demographic data and disease distribution for audited adult patients treated with 
biologics. Denominators differ when questions were not answered.  
General patient characteristics CD UC IBDU 
Total number of patients 1766 903 53 
Gender: male, % (n/N) 46% (812/1759) 59% (529/903) 49% (26/53) 
Age at diagnosis in years,  
median (IQR) 
n=1715 
27 (20, 40) 
n=900 
32 (24, 45) 
n=53 
32 (24, 45) 
Age at initial treatment in years, 
median (IQR) 
n=1766 
36 (26, 49) 
n=900 
39 (28, 52) 
n=53 
34 (27, 51) 
Time from diagnosis to treatment 
in years, median (IQR) 
n=1715 
4 (1, 11.3) 
n=903 
3.4 (1.3, 7.7) 
n=53 
2.2 (1.1, 6.8) 
Disease distribution, % (n/N) 
Terminal ileum (L1) 31% (540/1761)   - - 
Colonic (L2)  25% (444/1761)   - - 
Ileocolonic (L3)  38% (677/1761)   - - 
None of these 6% (100/1761)   - - 
Any part of the gut proximal to 
the terminal ileum (L4) 30% (404/1366)   - - 
Perianal involvement 19% (342/1766)   - - 
Proctitis (E1) - 11% (103/903)  2% (1/53)  
Left sided (E2) - 46% (412/903)  34% (18/53)  
Extensive (E3) - 43% (388/903)  64% (34/53)  
CD = Crohn’s disease; IBDU = inflammatory bowel disease unclassified; IQR = interquartile range; UC = ulcerative colitis. 
 
Table 3 Pre-treatment screening – adult patients 
The table below shows the percentage of adult patients that had adequate pre-treatment screening 
between 1 March 2015 and 29 February 2016. This analysis excludes data collected in PANTs.5  
Patients with adequate 
screening prior to treatment* CD UC IBDU Total 
Total number of patients 1352 903 53 2308 
Screening completed, % (n) 60% (814) 61% (546) 53% (28) 60% (1388) 
Incomplete screening, % (n) 39% (528) 39% (352) 47% (25) 39% (905) 
No screening, % (n) 0.6% (10) 0.6% (5) 0% (0) 0.7% (15) 
CD = Crohn’s disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative colitis. 
*Patients that had chest X-ray, either Gamma interferon or Mantoux screen, hepatitis B, hepatitis C and HIV screen.  
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Table 4 Pre-treatment screening by type – adult patients 
The table below shows the percentage of adult patients that have had pre-treatment screening by type 
of screening performed. Data collected in PANTs5 have not been included in this analysis. 
 Screening undertaken , % (n/N) 
Screening type Yes No Not indicated 
Chest X-ray 88% (2039/2308) 9% (199/2308) 3% (70/2308) 
CD 89% (1198/1352) 8% (110/1352) 3% (44/1352) 
UC  88% (792/903) 9% (85/903) 3% (26/903) 
IBDU 93% (49/53) 8% (4/53) 0% (0/53) 
Gamma interferon  / Mantoux screen 82% (1886/2308)  10% (233/2308) 8% (189/2308) 
CD  82% (1114/1352) 10% (134/1352) 8% (104/1352) 
UC  81% (731/903)  10% (93/903) 9% (79/903) 
IBDU 77% (41/53) 11% (6/53) 11% (6/53) 
Hepatitis B serology 95% (2196/2308) 4% (81/2308) 1% (31/2308) 
CD  95% (1286/1352) 3% (45/1352) 2% (21/1352) 
UC 95% (859/903) 4% (34/903) 1% (10/903) 
IBDU 96% (51/53) 4% (2/53) 0% (0/53) 
Hepatitis C serology 94% (2164/2308) 5% (109/2308) 2% (34/2308) 
CD  94% (1266/1352) 5% (62/1352) 2% (23/1352) 
UC  94% (848/903) 5% (45/903) 1% (10/903) 
IBDU 94% (50/53) 4% (2/53) 2% (1/53) 
HIV screen 80% (1846/2308) 14% (322/2308) 6% (139/2308) 
CD  79% (1061/1352) 15% (199/1352) 7% (91/1352) 
UC  82% (744/903) 12% (112/903) 5% (47/903) 
IBDU 77% (41/53) 21% (11/53) 2% (1/53) 
Varicella screen 84% (1941/2308) 11% (251/2308) 5% (115/2308) 
CD  83% (1124/1352) 12% (161/1352) 5% (66/1352) 
UC 86% (775/903) 9% (84/903) 5% (44/903) 
IBDU 79% (42/53) 11% (6/53) 9% (5/53) 
Stool cultures  50% (1157/2308) 34% (793/2308) 16% (357/2308) 
CD  43% (580/1352) 39% (522/1352) 18% (249/1352) 
UC  60% (544/903) 28% (256/903) 11% (103/903) 
IBDU 62% (33/53) 28% (15/53) 9% (5/53) 
C. difficile test 42% (963/2308) 39% (890/2308) 20% (454/2308) 
CD 35% (477/1352) 42% (569/1352) 23% (306/1352) 
UC 50% (455/903) 34% (305/903) 16% (142/903) 
IBDU 59% (31/53) 30% (16/53) 11% (6/53) 
CD = Crohn’s disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative colitis. 
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Table 5 Analysis of results over time – adult results 
This table compares some key results over time for adults with IBD included in the audit according to 
reporting timescales.  
Result 
Audit period 
12 Sep 2011 
– 
29 Feb 2012 
1 Mar 2012 
–  
28 Feb 2013 
1 Mar 2013 
–  
28 Feb 2014 
1 Mar 2014 
–  
28 Feb 2015 
1 Mar 2015 
–  
29 Feb 2016 
Participation in the biological therapy audit 
Adult sites with data 
included in analysis (n) 99 114 158 159 161 
Adult patients audited initiating biological therapies 
Patients with CD (n) 426 1026 1509 1943 1766 
Patients with UC (n) 62 184 281 412 903 
Patients with IBDU (n) 22 33 33 41 53 
Total (n) 510 1243 1823 2396 2722 
Treatment time 
Time from diagnosis to 
initial treatment in 
years, median (IQR) 
n= 510 
4.5 (1.4, 11.5) 
n=1243 
4.3 (1.0, 10.3) 
n=1819 
4.2 (1.1, 11.2) 
n=2387 
3.6 (0.9, 10.5) 
n=2671 
3.8 (1.1, 9.6)* 
Adverse reactions reported at initial treatment for adult patients 
Adverse reactions,  
% (n/N) 
3%  
(17/510) 
3%  
(32/1243) 
2%  
(44/1823) 
2%  
(54/2396) 
4% 
(117/2722) 
Disease activity reported at initial treatment for adult patients 
HBI score,  
median (IQR) 
n=266 
6 (0, 10) 
n=498 
9 (6, 11) 
n=782  
8 (4, 11) 
n=1125 
8 (4, 10) 
n=927 
7 (4, 10) 
SCCAI score,  
median (IQR) 
n=121 
0 (0, 4) 
n=105 
9 (6, 11) 
n=124 
9 (6, 11) 
n=178 
9 (6, 11) 
n=409 
7 (5, 10) 
Adult patients on concomitant therapies at initial treatment 
Immunosuppressants 
% (n/N) 
53% 
(271/510) 
57% 
(712/1243) 
52% 
(954/1823) 
53% 
(1263/2396) 
52% 
(1403/2722) 
Steroids 
% (n/N) 
28% 
(140/510) 
29% 
(365/1243) 
31% 
(562/1823) 
31% 
(745/2396) 
36% 
(969/2722) 
Adult patients on concomitant therapies at 3-month follow-up 
Immunosuppressants 
% (n/N) 
45%  
(83/184) 
56% 
(253/456) 
51% 
(387/753) 
49% 
(501/1032) 
45% 
(385/855) 
Steroids 
% (n/N) 
7%  
(13/184) 
5%  
(23/456) 
16% 
(122/753) 
18% 
(189/1032) 
21% 
(176/855) 
Surgery 
Surgery for IBD, 
% (n/N) 
36% 
(184/510) 
30% 
(376/1243) 
27% 
(493/1823) 
22% 
(514/2396) 
15% 
(412/2722) 
Surgery 6 months before 
starting biological 
therapies, % (n/N) 
6%  
(29/510) 
6%  
(74/1243) 
5%  
(92/1823) 
4%  
(85/2396) 
3%  
(68/2722) 
Surgery 6 months after 
starting biological 
therapies, % (n/N) 
6%  
(32/510) 
4%  
(55/1243) 
3%  
(60/1823) 
2%  
(54/2396) 
2%  
(52/2722) 
*p=0.026  
Immunosuppressants include azathioprine, mercaptopurine and methotrexate. †Steroids include budesonide, hydrocortisone, 
methylprednisolone and prednisolone. CD = Crohn’s disease; HBI = Harvey–Bradshaw index; IBDU = inflammatory bowel 
disease unclassified; IQR = interquartile range; SCCAI = Simple Clinical Colitis Activity Index; UC = ulcerative colitis. 
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Table 6 National comparison of key results – adult patients 
This table depicts national variation in the results of the biological therapy audit between England, 
Northern Ireland, Scotland and Wales. It only includes sites that submitted enough data to be included 
in the national analysis. A full list of participating and non-participating sites can be found in section 7, 
pp 53–79 of this report. 
Result 
Country 
England Northern Ireland Scotland Wales 
Sites participating in the audit (n) 139 4 8 10 
Patients audited (n) 2491 38 91 102 
Time from diagnosis to initial treatment  
in years, median (IQR) 
n=2442 
3.8 (1.1, 9.9) 
n=38 
5.2 (2.6, 10.2) 
n=89 
4.1 (1.4, 9.4) 
n=102 
2.9 (0.8, 7.5) 
Patients with an adverse reaction 
recorded during initial treatment % (n/N) 
5%  
(115/2491) 
8%  
(3/38) 
3%  
(3/91) 
6%  
(6/102)  
Disease severity (HBI) at initial 
treatment, median (IQR) 
n=868 
7 (4, 10) n=2 
n=22 
5 (3, 9) 
n=35 
8 (7, 13) 
Patients with follow-up recorded at 
3 months, % (n/N) 
32% 
(796/2491)  
24%  
(9/38) 
18%  
(16/91) 
33%  
(34/102) 
Patients on biological therapy who were 
appropriately prescribed anti-TNFα in 
compliance with NICE technology 
appraisal 1872 criterion 1.1, % (n/N) 
46%  
(399/868) 
50%  
(1/2) 
36%  
(8/22) 
63%  
(22/35) 
HBI = Harvey–Bradshaw index; IQR = interquartile range; TNFα = tumour necrosis factor alpha. 
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Audit objective – safety 
 
Table 7 Adverse reaction by biologic/biosimilar – adult patients 
This table shows the percentage of all adult patients for whom an adverse reaction was recorded by 
type of biologic used as treatment. 
Biologic/biosimilar 
Adverse reaction recorded = Yes 
Initial treatment 3-month follow-up 
Adalimumab (Humira) 3% (38/1154) 12% (42/343) 
Golimumab 9% (6/64) 9% (2/23) 
Infliximab biosimilar (Inflectra/Remsima) 5% (27/596) 11% (17/153) 
Infliximab (Remicade) 5% (40/800) 7% (21/305) 
Vedolizumab 15% (16/108) 0% (0/31) 
 
Table 8 Adverse reaction by type – adult patients 
This table shows the percentage of all adult patients for whom an adverse reaction was recorded by 
type of reaction. 
Adverse reactions % (n) Initial treatment (n=2722) 
3-month follow-up 
(n=855) 
Adverse reaction recorded 
Yes= 5% (127) 10% (82) 
Abdominal pain 0% (1) 0.1% (1) 
Alopecia 0% (0) 0.1% (1) 
Angioedema of upper airway 0% (0) 0.1% (1) 
Arthralgia 0.1% (3)  1% (10) 
Blood abnormality 0% (1) 0.4% (3) 
Bronchospasm (cough/wheeze/dyspnoea) 0% (0) 0.2% (2)  
Cardiac failure 0% (0) 0% (0) 
Chest pain 0% (1) 0.2% (2)  
Chills 0% (0) 0% (0) 
Confirmed demyelination 0% (0) 0% (0) 
Death 0% (0) 0% (0) 
Difficulty breathing 0% (0) 0.2% (2)  
Dizziness 0.1% (3) 0.1% (1) 
Fatigue 0.1% (2) 0% (0) 
Fever 0% (1) 0.1% (1) 
Flushing 0.1% (3) 0.2% (2)  
Headache 0.2% (5) 1% (9) 
Hypotension 0% (1) 0% (0) 
Infection 0.2% (5) 1% (9) 
Injection site reaction 0% (1) 0.6% (5) 
Itching 0.1% (3) 0.2% (2)  
Limb weakness 0% (0) 0% (0) 
Malignancy 0% (0) 0% (0) 
Nausea 0.3% (7) 0.4% (3) 
Panic attacks 0% (1) 0.1% (1) 
Rash 0.4% (12) 3% (23) 
Serum sickness-like reaction 0.1% (3)  0% (0) 
Urticaria 0% (0) 0% (0) 
Other 0.3% (9) 3% (24) 
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Audit objective – efficacy 
Disease activity for adult patients at the time of initial treatment was compared with that at the follow-
up nearest to 3 months from the date of the initial treatment. Follow-up data include only those 
patients who had an initial treatment. 
 
Table 9 Disease activity CD – adult patients  
When severity of CD in adult patients is classified by the Harvey–Bradshaw index (HBI), a score <5 is 
considered to be clinical remission and >16 is considered to be severe disease.  
Biologic/biosimilar 
HBI score – Median (IQR) 
Initial treatment 3-month follow-up 
Adalimumab (Humira), median (IQR) n=442 8 (4, 10) 
n=174 
3 (1, 6) 
Infliximab (Remicade), median (IQR) n=269 6 (4, 10) 
n=137 
2 (1, 5) 
Golimumab, median (IQR) n=2 n=0 
Infliximab biosimilar (Inflectra/Remsima), median (IQR) n=199 7 (5, 10) 
n=73 
3 (1, 5) 
Vedolizumab, median (IQR) n=15 9 (6, 12) 
n=3 
3 (2, 5) 
Total, median (IQR) n=927 7 (4, 10) 
n=387 
3 (1, 5) 
HBI = Harvey–Bradshaw index; IQR = interquartile range. 
 
Table 10 Response to therapy and remission by biologic/biosimilar – adult patients 
This table shows response* to therapy and remission at 3-month follow-up in adult patients by 
biologic/biosimilar type.  
Biologic/biosimilar Response Remission 
Adalimumab (Humira) 76% (127/168) 61% (106/174) 
Infliximab biosimilar (Inflectra/Remsima) 84% (59/70) 69% (50/73) 
Infliximab (Remicade) 85% (114/134) 74% (103/139) 
Vedolizumab (Entyvio) 67% (2/3) 67% (2/3) 
*Response is defined as decrease of >3 in Harvey–Bradshaw index for adult patients 
Remission is defined as Harvey–Bradshaw index (HBI) score <4 for adult patients 
 
Table 11 Response to therapy – adult patients 
This table shows response* to therapy at 3-month follow-up in adult patients with CD who were treated 
with a biologic or biosimilar. The Harvey–Bradshaw index (HBI) is used to quantify disease activity for 
adult patients with CD. The denominators change when dates of diagnosis for patients are missing. 
 Time from diagnosis to initial treatment in years 
Response to therapy <1 1–2 3–5 6–10 >10 Total 
CD National data  
% (n/N) 
84%  
(76/91)  
80%  
(53/66)  
85%  
(50/59)  
78%  
(45/58)  
77%  
(63/82)  
81% 
(287/356)  
*Response is defined as decrease of >3 in Harvey–Bradshaw index for adult patients 
CD = Crohn’s disease.  
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Table 12 Remission achieved – adult patients 
This table shows whether remission* was achieved at 3-month follow-up in adult patients with CD who 
were treated with a biologic or biosimilar. As before, the HBI was used to quantify disease activity in 
adults with CD. The denominators change when dates of diagnosis for patients are missing. 
Time from diagnosis to initial treatment in years 
Remission achieved <1 1–2 3–5 6–10 >10 Total 
CD National data 
% (n/N) 
64% 
(61/95) 
68% 
(46/68) 
75% 
(45/60) 
61% 
(37/61) 
69% 
(59/86) 
67% 
(248/370) 
*Remission is defined as Harvey–Bradshaw index (HBI) score <4 for adult patients
CD = Crohn’s disease. 
Table 13 Disease activity UC – adult patients 
When severity of UC in adult patients is classified by SCCAI, a score of <3 is considered to be remission 
and >13 is considered to be severe disease.  
SCCAI score – Median (IQR) 
Biologic/biosimilar Initial treatment 3-month follow-up 
Adalimumab (Humira), median (IQR) n=103 6 (4, 8) 
n=15 
4 (2, 7) 
Infliximab (Remicade), median (IQR) n=106 9 (6, 11) 
n=31 
2 (1, 7) 
Golimumab, median (IQR) n=35 7 (5, 9) 
n=5 
7 (7, 10) 
Infliximab biosimilar (Inflectra/Remsima), median (IQR) n=115 8 (6, 10) 
n=22 
4 (2, 6) 
Vedolizumab, median (IQR) n=36 6 (5, 8) 
n=9 
5 (2, 6) 
Total, median (IQR) n=395 7 (5, 10) 
n=82 
4 (1, 7) 
IQR = interquartile range; SCCAI = Simple Clinical Colitis Activity Index.
25 
© Healthcare Quality Improvement Partnership 2016 
National clinical audit of biological therapies. Annual report. September 2016. UK IBD audit 
 
Table 14 Infliximab (Remicade) vs infliximab biosimilar (Inflectra/Remsima) – adult patients 
This table compares data entered to the audit on adult patients being treated with either infliximab 
(Remicade) or its biosimilar (Inflectra/Remsima) between 1 March 2015 and 29 February 2016. 
 Infliximab (Remicade) Infliximab biosimilar (Inflectra/Remsima) 
General patient characteristics 
Gender: male, % (n/N) 53% (421/799) 51% (300/593) 
Age at diagnosis, years, median (IQR) n=790 28 (20, 42) 
n=579 
30 (22, 43) 
Age at initial treatment, years, median 
(IQR) 
n=800 
35 (26, 50) 
n=595 
37 (27, 52) 
Time from diagnosis to treatment, years,  
median (IQR) 
n=790 
3.3 (0.9, 8.5) 
n=580 
3 (0.8, 9) 
Disease severity, median (IQR)   
HBI at initial treatment n=269 6 (4, 10) 
n=199 
7 (5, 10) 
HBI at 3-month follow-up n=137 2 (1, 5) 
n=73 
3 (1, 5) 
Response and remission at 3-month follow-up, % (n/N) 
Response to treatment 
(Response is defined as decrease of >3 in HBI for 
adult patients) 
85% (114/134) 84% (59/70) 
Remission achieved  
(Remission is defined as HBI score <4 for adult 
patients) 
74% (103/139) 69% (50/73) 
Adverse reactions, % (n/N)   
At initial treatment 5% (40/800) 5% (27/596) 
At 3-month follow-up 7% (21/305) 11% (17/153) 
Concomitant therapy, % (n/N)   
Concomitant therapy for IBD at initial 
treatment 81% (651/800) 80% (474/596) 
Immunosuppressants 
(Includes azathioprine, mercaptopurine and 
methotrexate) 
54% (430/800) 49% (291/596) 
Steroids 
(Includes budesonide, hydrocortisone, 
methylprednisolone and prednisolone) 
38% (304/800) 43% (255/596) 
HBI = Harvey–Bradshaw index; IBD = inflammatory bowel disease; IQR = interquartile range. 
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Audit objective – appropriateness of prescribing anti-TNFα  
Detailed information about the NICE guidance and recommendations for use of biological therapies in 
patients with IBD in the UK can be found in section 5, pp 47–48 of this report. In Tables 15 and 16, NICE 
criterion 1.1 from technology appraisal 1872 and criterion 1.1 from technology appraisal 3293 have been 
used to assess the appropriateness of prescribing biological therapy.  
Table 15 Compliance with NICE technology appraisal 187 criterion 1.1 
This table shows compliance with criterion 1.1 of NICE technology appraisal 1872 in adult patients with 
CD. Patients with no recorded HBI were excluded from this analysis. 
NICE technology appraisal 187 National CD data % (n/N) 
Criterion 1.1 Infliximab and adalimumab are recommended as treatment options for adults with 
severe active CD if (a) the disease has not responded to conventional therapy or (b) the person is 
intolerant of or has contraindications to conventional therapy (mercaptopurine, azathioprine, 
methotrexate, prednisolone, budesonide, methylprednisolone or hydrocortisone) 
CD patients with HBI score ≥8 before starting anti-TNFα treatment, % (n/N)  48% (448/927) 
CD patients with HBI scores who were treated with conventional therapy at 
time of or prior to starting anti-TNFα treatment, % (n/N) 93% (865/927) 
CD patients who were appropriately prescribed anti-TNFα treatment in 
compliance with criterion 1.1 of NICE technology appraisal 187, % (n/N) 46% (430/927) 
CD = Crohn’s disease; HBI = Harvey–Bradshaw index; NICE = National Institute for Health and Care Excellence; TNFα = tumour 
necrosis factor alpha. 
Table 16 Compliance with NICE technology appraisal 329 criterion 1.1 
This table shows compliance with criterion 1.1 of NICE technology appraisal 3293 in adult patients with 
UC. Patients with no recorded SCCAI were excluded from this analysis. 
NICE technology appraisal 329 National UC data % (n/N) 
Criterion 1.1 Infliximab, adalimumab and golimumab are recommended as treatment options for 
adults with moderate to severe active UC (a) whose disease has responded inadequately to 
conventional therapy or (b) who are intolerant of or have contraindications to conventional therapy 
(mercaptopurine, azathioprine, methotrexate, prednisolone, budesonide, methylprednisolone or 
hydrocortisone) 
UC patients with SCCAI score ≥5 before starting anti-TNFα treatment, % 
(n/N) 80% (314/395) 
UC patients with SCCAI scores who were treated with conventional therapy 
at time of or prior to starting anti-TNFα treatment, % (n/N) 92% (364/395) 
UC patients who were appropriately prescribed anti-TNFα therapy in 
compliance with criterion 1.1 of NICE technology appraisal 329, % (n/N) 74% (293/395) 
SCCAI = Simple Clinical Colitis Activity Index; NICE = National Institute for Health and Care Excellence; TNFα = tumour necrosis 
factor alpha; UC = ulcerative colitis. 
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Table 17 Concomitant therapy for IBD – adult patients 
This table shows the percentage of all adult patients on any immunosuppressants or steroids as 
concomitant therapy during their treatment with biological therapies.  
Type of concomitant therapy Initial treatment, % (n) 3-month follow-up, % (n) 
CD patients 1766 591 
Concomitant therapy for IBD = Yes 74% (1301) 65% (383) 
Immunosuppressants* 53% (931) 48% (284) 
Steroids† 29% (506) 21% (123) 
UC patients 903 247 
Concomitant therapy for IBD = Yes 87% (783) 70% (172) 
Immunosuppressants* 49% (443) 38% (94) 
Steroids† 48% (431) 21% (51) 
IBDU patients 53 17 
Concomitant therapy for IBD = Yes 83% (44) 65% (11) 
Immunosuppressants* 55% (29) 41% (7) 
Steroids† 60% (32) 12% (2) 
*Immunosuppressants include azathioprine, mercaptopurine and methotrexate.
†Steroids include budesonide, hydrocortisone, methylprednisolone and prednisolone.
CD = Crohn’s disease; IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative 
colitis.
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Audit objective – patient-reported outcome measures 
Outcome measures have traditionally relied on disease activity indexes, but these measures fail to 
assess the patient’s subjective view of their experience. Patient-reported outcome measures therefore 
evaluate quality from the patient’s perspective. Typically, they are short, self-completed questionnaires 
that measure the patient’s health status or health-related quality of life at a single point in time. The 
health status information is collected from patients by way of PROMs questionnaires completed before, 
during and after an intervention (in this case, initiation of biological therapy) and provides an indication 
of the outcomes or quality of care delivered to patients. 
EQ-5D 
The EQ-5D8 is a standardised instrument for use as a measure of health outcome. It provides a simple 
descriptive profile and a single index value for health status. It was primarily designed for self-
completion by respondents and is ideally suited for use in clinics.  
The EQ-5D is a descriptive system of health-related quality of life states consisting of five dimensions 
(mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each of which can take 
one of three responses depending on level of severity – no problems / some or moderate problems / 
extreme problems – within a particular EQ-5D dimension. Total EQ-5D scores range from 0 (worst health 
/ death) to 1 (best health), with an increase in score denoting improved health. Scores from each 
domain are weighted and converted into a single weighted summary index. The data within this report 
are presented in the form of a median (IQR). The EQ-5D has been shown to be valid, reliable and 
responsive in patients with IBD.9 
In total, 17% (471/2722) of patients completed an EQ-5D questionnaire at an initial treatment with a 
median (IQR) score of 0.76 (0.64, 0.8). At 3-month follow up 28% (242/855) of patients completed an 
EQ-5D questionnaire with a median (IQR) score of 0.8 (0.73, 1). The limited number of EQ-5D 
questionnaires completed at initial and follow-up treatment meant that a difference between these 
scores could not be calculated. However, the median scores at these two stages were calculated. A 
comparison of these scores showed an increase in the median EQ-5D score of 0.04 between initial and 
3-month follow-up. This may suggest clinical improvement in quality of life after patients have begun 
biological therapies. 
CUCQ-12 
The Crohn’s and ulcerative colitis questionnaire (CUCQ)-1210 is a relatively new and shortened version of 
the 32-item Crohn’s and Colitis questionnaire (CCQ-32) – a quality of life measurement tool developed 
specifically for use with patients with IBD to measure active disease and long-term monitoring of the 
condition.  
The items in the CUCQ-12 questionnaire address the following 12 dimensions: sleeping, appetite, energy 
level, rushing to the toilet, being bloated, incomplete emptying of bowels, blood in stool, generally 
unwell, faecal incontinence, nocturnal diarrhoea, passing wind and effect on leisure activity. Each 
question is scored between 0 (best health) and 14 (poor health), corresponding to the number of days 
affected by a parameter in a fortnight, giving a total CUCQ-12 score ranging from 0 (best health) to 168 
(poor health). Remission in patients with UC and CD is suggested by CUCQ-12 scores of <45 and <50, 
respectively. The minimum significant change in CUCQ-12 is 13 for both UC and CD. Early results have 
shown that the CUCQ-12 performs well in patients with IBD, with positive correlations compared with 
the EQ-5D and 12-item short-form (SF-12). 
29 
© Healthcare Quality Improvement Partnership 2016 
National clinical audit of biological therapies. Annual report. September 2016. UK IBD audit 
In total, 18% (483/2722) of patients completed a CUCQ-12 questionnaire at initial treatment. The 
median (IQR) score of 70 (38, 98) suggests active disease at this time point. At 3-month follow-up 29% 
(248/855) of patients completed a CUCQ-12 questionnaire with a median (IQR) score of 35 (15, 55). The 
limited number of CUCQ-12 questionnaires completed at initial and follow-up treatment meant that a 
difference between these scores could not be calculated. However, the median scores at these two 
stages were calculated. A comparison of these scores showed an increase in the median CUCQ-12 score 
of 35 between initial and follow-up treatment, which may suggest clinical improvement in quality of life 
following biological therapy. 
Table 18 PROMs questionnaire for adult patients (IBD-PROM) 
This table gives completion rates and results of the IBD-PROM questionnaires used in the biological 
therapies audit – the EQ-5D8 and CUCQ-1210 – for all adult patients calculated. Total EQ-5D scores range 
from 0 (worst health / death) to 1 (best health), with an increase in score denoting improved health. 
Total CUCQ-12 scores range from 0 (best health) to 168 (poor health), with each question scored 
between 0 (best) and 14 (poor).  
IBD-PROM Initial treatment 3-month follow-up 
Patients with EQ-5D data completed, % (n/N) 17% (471/2722) 28% (242/855) 
EQ-5D score, median (IQR) n=471 0.76 (0.64, 0.8) 
n=242 
0.8 (0.73, 1) 
Patients with CUCQ-12 data completed, % (n/N) 18% (483/2722) 29% (248/855) 
CUCQ-12 score, median (IQR) n=483 70 (38, 98) 
n=248 
35 (15, 55) 
CUCQ = Crohn’s and ulcerative colitis questionnaire; IBD = inflammatory bowel disease; IQR = interquartile range; PROMs = 
patient-reported outcome measures. 
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IBD-related surgery in adult patients 
 
Table 19 IBD-related surgery in adult patients with CD 
This table displays the surgical procedures in adult patients with CD by type of procedure and whether 
the surgery took place within the 6 months before or after starting biological therapies.  
CD-related surgery 
Adult patients with surgery recorded* 
(n=1827) 
Surgery 6 months 
before starting 
biological therapies 
(n=333) 
Surgery 6 months after 
starting biological 
therapies  
(n=176) 
Surgical procedure by type (%, n) 
Anterior resection 0.3% (1) - 
Appendicectomy 0.3% (1) - 
Cholecystectomy 0.3% (1) 0.6% (1) 
Colectomy and ileostomy 2% (8) 9% (15) 
Drainage of abscess 0.9% (3) 3% (5) 
Gastric surgery - 0.6% (1) 
Other surgical procedure 16% (54) 17% (30) 
Partial colectomy 0.6% (2) 3% (5) 
Perianal surgery 53% (177) 23% (40) 
Right hemicolectomy / ileocaecal resection 7% (23) 14% (24) 
Small bowel resection 7% (23) 23% (41) 
Stoma formation 2% (8) 4% (7) 
Stoma reversal 0.3% (1) - 
Stricturoplasty 2% (6) 3% (6) 
Total proctocolectomy permanent ileostomy 0.3% (1) 3% (5) 
Unknown procedure 14% (46) 2% (4) 
*Patients may have one or more surgeries recorded. 
CD = Crohn’s disease. 
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Table 20 IBD-related surgery in adult patients with UC 
This table displays the surgical procedures in adult patients with UC by type of procedure and whether 
the surgery took place within the 6 months before or after starting biological therapies.  
UC-related surgery 
Adult patients with surgery recorded* 
(n=133) 
Surgery 6 months 
before starting 
biological therapies 
(n=12) 
Surgery 6 months after 
starting biological 
therapies  
(n=68) 
Surgical procedure by type (%, n)  
Appendicectomy 8% (1) - 
Colectomy and ileostomy 25% (3) 75% (51) 
Other surgical procedure 42% (5) 4% (3) 
Partial colectomy - 9% (6) 
Perianal surgery 17% (2) 3% (2) 
Small bowel resection 8% (1) - 
Total proctocolectomy ileoanal pouch - 2% (1) 
Total proctocolectomy permanent ileostomy - 7% (5) 
*Patients may have one or more surgeries recorded. 
UC = ulcerative colitis. 
 
Table 21 IBD-related surgery in adult patients with IBDU 
This table displays the surgical procedures in adult patients with IBDU by type of procedure and whether 
the surgery took place within the 6 months before or after starting biological therapies.  
IBDU-related surgery 
Adult patients with surgery recorded* 
(n=19) 
Surgery 6 months 
before starting 
biological therapies 
(n=3) 
Surgery 6 months after 
starting biological 
therapies  
(n=9) 
Surgical procedure by type (%, n) 
Colectomy and ileostomy - 78% (7) 
Perianal surgery 100% (3) 22% (2) 
*Patients may have one or more surgeries recorded. 
IBDU = inflammatory bowel disease unclassified. 
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3: Key results – paediatric services 
 
Consort diagram for initial treatment – paediatric patients  
Between 1 March 2015 and 29 February 2016, 278 individual paediatric patient demographic 
submissions had been entered on the web tool.  
 
Fig 2 Consort diagram for initial treatment – paediatric patients   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD = Crohn’s disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative colitis. 
 
Fig 2 is integral to understanding the patient numbers and the reasons that patients were excluded from 
analysis when considering the results in this report. Readers are reminded that individual results are 
often a subset of this number and that the context and actual number of cases should be considered 
when interpreting findings. A consort diagram detailing patient numbers and reasons for exclusion from 
follow-up treatment data can be found in Appendix 3, p 83.
n=21 
Adalimumab (Humira) patients: 
CD (n=19) 
UC (n=1) 
IBDU (n=1) 
n=175 
Infliximab (Remicade) patients: 
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Initial treatments 
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Patients with  
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Patients with  
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initial treatment analysis 
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Infliximab biosimilar 
(Inflectra/Remsima) patients: 
CD (n=63) 
UC (n=14) 
IBDU (n=5) 
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The results in this section should not be directly compared with any previous biological therapy audit 
report. This is due to sites being able to lock and unlock any case entered to the audit since its 
inception and amend data retrospectively.  
Only patients with at least one initial treatment were included in the analyses. Thereafter, the numbers 
reduce based on whether patients were recorded as having been followed up at 3 and 12 months after 
initial treatment. For the follow-up time point, a 1-month window either side was used in order to best 
capture patients – eg for 3-month follow-up, data entered 60–120 days after initial treatment were 
included. 
Table 22 Paediatric patient summary (2016 audit data) 
This table provides a summary of the paediatric patients and their treatments included in the national 
analysis between 1 March 2015 and 29 February 2016. 
2016 audit data Patient group 
Treatment and biologics type CD UC IBDU All IBD 
Initial treatment (n=211) (n=47) (n=20) (n=278) 
Adalimumab (Humira) 9% (19) 2% (1) 5% (1) 8% (21) 
Infliximab biosimilar (Inflectra/Remsima) 30% (63) 30% (14) 25% (5) 29% (82) 
Infliximab (Remicade) 61% (129) 68% (32) 70% (14) 63% (175) 
3-month follow-up (n=93) (n=19) (n=9) (n=121) 
Adalimumab (Humira) 5% (5) - 11% (1) 5% (6) 
Infliximab biosimilar (Inflectra/Remsima) 37% (34) 21% (4) 11% (1) 32% (39) 
Infliximab (Remicade) 58% (54) 79% (15) 78% (7) 63% (76) 
12-month follow-up (n=1) (n=0) (n=0) (n=1) 
Adalimumab (Humira) - - - - 
Infliximab biosimilar (Inflectra/Remsima) - - - - 
Infliximab (Remicade) 100% (1) - - 100% (1) 
CD = Crohn’s disease; IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative 
colitis. 
Table 23 Paediatric patient summary (2011–2016 audit data) 
This table provides a summary of the paediatric patients and their treatments included in the national 
analysis between 12 September 2011 and 29 February 2016. 
2011–2016 audit data Patient group 
Treatment and biologics type CD UC IBDU All IBD 
Initial treatment (n=842) (n=149) (n=59) (1050) 
Adalimumab (Humira) 6% (51) 4% (6) 3% (2) 6% (59) 
Infliximab biosimilar (Inflectra/Remsima) 8% (63) 9% (14) 9% (5) 8% (82) 
Infliximab (Remicade) 87% (728) 87% (129) 88% (52) 87% (909) 
3-month follow-up (n=452) (n=53) (n=30) (535) 
Adalimumab (Humira) 9% (40) 2% (1) 7% (2) 8% (43) 
Infliximab biosimilar (Inflectra/Remsima) 8% (34) 8% (4) 3% (1) 7% (39) 
Infliximab (Remicade) 84% (378) 91% (48) 90% (27) 85% (453) 
12-month follow-up (n=228) (n=13) (n=4) (245) 
Adalimumab (Humira) 7% (16) - - 7% (16) 
Infliximab biosimilar (Inflectra/Remsima) - - - - 
Infliximab (Remicade) 93% (212) 100% (13) 100% (4) 94% (229) 
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Table 24 Key demographic items data – paediatric patients 
Table 24 compares demographic data and disease distribution for audited paediatric patients treated 
with biologics between 12 September 2011 and 29 February 2016. Denominators differ when questions 
were not answered. 
General patient characteristics CD UC IBDU All IBD 
Total number of patients 842 149 59 1050 
Gender: male, % (n/N) 64% (541/841) 51% (76/149) 64% (38/59) 62% (655/1049) 
Age at diagnosis in years,  
median (IQR) 
n=837 
12 (10, 14) 
n=149 
12 (9, 14) 
n=59 
12 (10, 14) 
n=1045 
12 (10, 14) 
Age at initial treatment in years, 
median (IQR) 
n=841 
14 (12, 15) 
n=149 
14 (12, 15) 
n=59 
14 (12, 16) 
n=1049 
14 (12, 15) 
Time from diagnosis to treatment 
in years, median (IQR) 
n=838 
1.1 (0.5, 2.4) 
n=149 
1.1 (0.3, 2.2) 
n=59 
0.9 (0.4, 2.4) 
n=1046 
1.1 (0.5, 2.4) 
Disease distribution, % (n) 
Terminal ileum (L1) 12% (103) - - 10% (103) 
Colonic (L2) 28% (234) - - 22% (234) 
Ileocolonic (L3) 51% (433) - - 41% (433) 
None of these 9% (72) - - 7% (72) 
Any part of the gut proximal to 
the terminal ileum (L4) 58% (487) - - 46% (487) 
Perianal involvement 34% (285) - - 27% (285) 
Proctitis (E1) - 9% (14) 0% (0) 1% (14) 
Left sided (E2) - 20% (30) 15% (9) 4% (39) 
Extensive (E3) - 71% (105) 85% (50) 15% (155) 
CD = Crohn’s disease; IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative 
colitis. 
 
Table 25 Pre-treatment screening – paediatric patients 
Table 25 shows the percentage of paediatric patients that had adequate pre-treatment screening 
between 1 March 2015 and 29 February 2016. PANTs data was not included in this analysis. 
Patients with adequate 
screening prior to treatment* CD UC IBDU All IBD 
Total number of patients 163 47 20 230 
Screening completed, % (n) 45% (73) 60% (28) 40% (8) 47% (109) 
Incomplete screening, % (n) 55% (89) 40% (19) 60% (12) 52% (120) 
No screening, % (n) 0.6% (1) 0% (0) 0% (0) 0.4% (1) 
*Patients that had chest X-ray, screening for hepatitis B and either Mantoux or Gamma interferon. 
CD = Crohn’s disease; IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative 
colitis. 
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Table 26 Pre-treatment screening by type – paediatric patients 
The table below shows the percentage of paediatric patients that have had pre-treatment screening by 
type of screening performed between 1 March 2015 and 29 February 2016. Data collected in PANTs 
have not been included in this analysis. 
Screening undertaken, % (n/N) 
Screening type Yes No Not indicated 
Chest X-ray 92% (211/230) 7% (16/230) 1% (3/230) 
CD 89% (145/163) 9% (15/163) 2% (3/163) 
UC 100% (47/47) 0% (0/47) 0% (0/47) 
IBDU 95% (19/20) 5% (1/20) 0% (0/20) 
Gamma interferon  / Mantoux screen 81% (187/230) 18% (42/230) 0.4% (1/230) 
CD 84% (137/163) 16% (26/163) 0% (0/163) 
UC 77% (36/47) 21% (10/47) 2% (1/47) 
IBDU 70% (14/20) 30% (6/20) 0% (0/20) 
Hepatitis B serology 61% (140/230) 34% (79/230) 5% (11/230) 
CD 58% (94/163) 37% (60/163) 6% (9/163) 
UC 75% (35/47) 21% (10/47) 4% (2/47) 
IBDU 55% (11/20) 45% (9/20) 0% (0/20) 
Hepatitis C serology 47% (107/230) 47% (109/230) 6% (14/230) 
CD 44% (72/163) 50% (81/163) 6% (10/163) 
UC 62% (29/47) 32% (15/47) 6% (3/47) 
IBDU 30% (6/20) 65% (13/20) 5% (1/20) 
HIV screen 11% (25/230) 67% (153/230) 23% (52/230) 
CD 9% (15/163) 66% (107/163) 25% (41/163) 
UC 17% (8/47) 64% (30/47) 19% (9/47) 
IBDU 10% (2/20) 80% (16/20) 10% (2/20) 
Varicella screen 85% (196/230) 10% (23/230) 5% (11/230) 
CD 85% (139/163) 10% (17/163) 4% (7/163) 
UC 85% (40/47) 9% (4/47) 6% (3/47) 
IBDU 85% (17/20) 10% (2/20) 5% (1/20) 
Stool cultures 54% (124/230) 34% (78/230) 12% (28/230) 
CD 47% (77/163) 39% (63/163) 14% (23/163) 
UC 77% (36/47) 19% (9/47) 4% (2/47) 
IBDU 55% (11/20) 30% (6/20) 15% (3/20) 
C. difficile test 42% (96/230) 44% (102/230) 14% (32/230) 
CD 35% (57/163) 50% (81/163) 15% (25/163) 
UC 62% (29/47) 26% (12/47) 13% (6/47) 
IBDU 50% (10/20) 45% (9/20) 5% (1/20) 
CD = Crohn’s disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative colitis. 
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Table 27 Analysis of paediatric patient results over time 
This table displays results over time, according to reporting timescales, for paediatric patients with IBD.  
Result 
Audit period 
12 Sep 2011 
– 29 Feb 
2012 
1 Mar 2012 
– 28 Feb 
2013 
1 Mar 2013 
– 28 Feb 
2014 
1 Mar 2014 
– 28 Feb 
2015 
1 Mar 2015 
– 29 Feb 
2016 
Participation in the biological therapy audit 
Paediatric sites with data 
included in analysis (n) 20 24 29 31 27 
Paediatric patients audited initiating biological therapies 
Patients with CD (n) 75 159 171 226 211 
Patients with UC (n) 8 32 30 32 47 
Patients with IBDU (n) 2 7 11 19 20 
Total (n) 85 198 212 277 278 
Treatment time 
Time from diagnosis to 
initial treatment in years, 
median (IQR) 
n=85 
1.2 (0.5, 2.9) 
n=198 
1.3 (0.6, 2.4) 
n=212 
1.1 (0.5, 2.3) 
n=277 
1 (0.4, 2.2) 
n=274 
0.9 (0.4, 2.4) 
Adverse reactions reported at initial treatment for paediatric patients 
Adverse reactions  
% (n/N) 
2%  
(2/85) 
1%  
(2/198) 
0.5%  
(1/212) 
3%  
(7/277) 
1%  
(4/278) 
Disease activity reported at initial treatment for paediatric patients 
PCDAI score,  
median (IQR) 
n=52  
20 (5, 33) 
n=100  
30 (20, 40) 
n=94  
30 (15, 40) 
n=109 
25 (15, 35) 
n=71  
33 (20, 43) 
wPCDAI score, 
 median (IQR) n=1 n=2 n=3 
n=9  
55 (48, 60) 
n=23  
50 (35, 65) 
PUCAI score,  
median (IQR) 
n=22  
0 (0, 35) 
n=31  
55 (40, 65) 
n=23  
65 (43, 78) 
n=24  
34 (20, 65) 
n=35 
50 (30, 65) 
Paediatric patients on concomitant therapies at initial treatment 
Immunosuppressants*  
% (n/N) 
84%  
(71/85) 
79% 
(156/198) 
82% 
(173/212) 
85% 
(234/277) 
84%  
(234/278) 
Steroids†  
% (n/N) 
27%  
(23/85) 
37%  
(74/198) 
28%  
(59/212) 
28%  
(78/277) 
28%  
(78/278) 
Paediatric patients on concomitant therapies at 3-month follow-up treatment 
Immunosuppressants*  
% (n/N) 
86%  
(43/50) 
77%  
(75/97) 
83%  
(87/105) 
90% 
(146/162) 
80%  
(97/121) 
Steroids†  
% (n/N) 
0%  
(0/50) 
7%  
(7/97) 
14%  
(15/105) 18% (29/162) 
17%  
(21/121) 
Surgery      
Surgery for IBD, 
% (n/N) 
25%  
(21/85) 
25%  
(49/198) 
14%  
(29/212) 
12%  
(34/277) 
8%  
(23/278) 
Surgery 6 months before 
starting biological 
therapies, % (n/N) 
8%  
(7/85) 
8%  
(15/198) 
5%  
(10/212) 
4%  
(11/277) 
4%  
(11/278) 
Surgery 6 months after 
starting biological 
therapies, % (n/N) 
5%  
(4/85) 
5%  
(10/198) 
6%  
(12/212) 
5%  
(13/277) 
2%  
(5/278) 
CD = Crohn’s disease; HBI = Harvey–Bradshaw index; IBDU = inflammatory bowel disease unclassified; IQR = interquartile range; 
SCCAI = Simple Clinical Colitis Activity Index; UC = ulcerative colitis. *Immunosuppressants include azathioprine, 
mercaptopurine and methotrexate. †Steroids include budesonide, hydrocortisone, methylprednisolone and prednisolone. 
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Audit objective – safety 
Table 28 Adverse reaction by biologic/biosimilar – paediatric patients 
This table shows the percentage of all paediatric patients audited between 1 March 2015 and 29 
February 2016 for whom an adverse reaction was recorded by type of biologic used as treatment. 
Biologic/biosimilar 
Adverse reactions recorded = Yes, % (n/N) 
Initial treatment 3-month follow-up 
Adalimumab (Humira) 5% (1/21) 0% (0/6) 
Infliximab biosimilar (Inflectra/Remsima) 0% (0/82) 5% (2/39) 
Infliximab (Remicade) 2% (3/175) 5% (4/76) 
Table 29 Adverse reactions by type – paediatric patients 
This table shows the percentage of all paediatric patients for whom an adverse reaction was recorded 
by type of reaction between 1 March 2015 and 29 February 2016. 
Adverse reactions, % (n) Initial treatment (n=278) 
3-month follow-up 
(n=121) 
Adverse reaction recorded 
Yes= 1% (4) 5% (6) 
Abdominal pain 0% (0) 0% (0) 
Alopecia 0% (0) 0% (0) 
Angioedema of upper airway 0% (0) 0% (0) 
Arthralgia 0% (0) 0% (0) 
Blood abnormality 0% (0) 0.8% (1) 
Bronchospasm (cough/wheeze/dyspnoea) 0% (0) 0% (0) 
Cardiac failure 0% (0) 0% (0) 
Chest pain 0% (0) 0% (0) 
Chills 0% (0) 0% (0) 
Confirmed demyelination 0% (0) 0% (0) 
Death 0% (0) 0% (0) 
Difficulty breathing 0% (0) 0.8% (1) 
Dizziness 0% (0) 0% (0) 
Fatigue 0% (0) 0% (0) 
Fever 0% (0) 2% (2) 
Flushing 0% (0) 0% (0) 
Headache 0% (0) 0% (0) 
Hypotension 0% (0) 0% (0) 
Infection 0% (0) 0% (0) 
Injection site reaction 0% (0) 0% (0) 
Itching 0% (0) 0% (0) 
Limb weakness 0% (0) 0% (0) 
Malignancy 0% (0) 0% (0) 
Nausea 0% (0) 0% (0) 
Panic attacks 0% (0) 0% (0) 
Rash 0% (0) 2% (2) 
Serum sickness-like reaction 0% (0) 0% (0) 
Urticaria 0% (0) 0% (0) 
Other 0.4% (1) 2% (2) 
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Audit objective – efficacy 
Disease activity for paediatric patients at the time of initial treatment was compared with that at the 
follow-up nearest to 3 and 12 months from the date of the initial treatment. Follow-up data include only 
those patients who had an initial treatment. 
 
Table 30 Disease activity as defined by the Paediatric Crohn’s Disease Activity Index (PCDAI) 
This table shows the severity of disease as defined by PCDAI documented at baseline, 3- and 12-month 
review for data entered to the audit between 12 September 2011 and 29 February 2016. When severity 
of CD for paediatric patients is classified by PCDAI, a score <10 is considered to be clinical remission and 
>40 is considered to be severe disease.  
PCDAI score Initial treatment 
3-month  
follow-up 
12-month 
follow-up 
Adalimumab (Humira), median (IQR) n=9 20 (10, 38) 
n=17 
20 (8, 30) n=1 
Infliximab (Remicade), median (IQR) n=388 28 (18, 40) 
n=194 
5 (0, 15) 
n=115 
10 (0, 23) 
Infliximab biosimilar (Inflectra/Remsima 
combined), median (IQR) 
n=29 
28 (20, 40) 
n=15 
0 (0, 8) n=0 
Total, median (IQR) n=426 28 (18, 40) 
n=226 
6 (1, 15) 
n=116 
10 (0, 23) 
IQR = interquartile range; PCDAI = Paediatric Crohn’s Disease Activity Index. 
 
Table 31 Response to therapy and remission – paediatric patients 
This table shows response to therapy and whether remission was achieved in paediatric patients with 
CD. Results are displayed at the 3-month time point. The PCDAI is used to quantify the disease activity 
for paediatric patients. Response is defined as PCDAI decrease of >15 and remission is defined as a 
PCDAI score of <10. 
Audit period Response
* to treatment at 3-
month follow-up, % (n/N) 
Remission achieved at 3-month 
follow-up, % (n/N) 
2016 audit data 
(1 Mar 2015 – 29 Feb 2016) 86% (50/58) 72% (46/64) 
2011 – 2016 audit data 
(12 Sep 2011 – 29 Feb 2016) 77% (208/272) 67% (190/284) 
*Response is defined as PCDAI decrease of >15 
Remission is defined as a PCDAI score of <10 
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Table 32 Disease activity as defined by the weighted Paediatric Crohn’s Disease Activity Index 
(wPCDAI) 
This table shows the severity of disease defined by wPCDAI documented at baseline, 3- and 12-month 
review for data entered to the audit between 12 September 2011 and 29 February 2016. Severity of CD 
classified by wPCDAI a score of <12.5 is considered to be clinical remission and >57.5 severe disease.  
wPCDAI score Initial treatment 
3-month 
follow-up 
12-month 
follow-up 
Adalimumab (Humira), median (IQR) n=2 n=3 n=4 10 (0, 28) 
Infliximab (Remicade), median (IQR) n=28 51 (35, 64) 
n=11 
0 (0, 15) 
n=4 
15 (5, 28) 
Infliximab biosimilar (Inflectra/Remsima 
combined), median (IQR) 
n=8 
44 (26, 60) 
n=6 
11 (8, 15) n=0 
Total, median (IQR) n=38 51 (35, 65) 
n=20 
11 (0, 16) 
n=8 
15 (0, 28) 
IQR = interquartile range; wPCDAI = weighted Paediatric Crohn’s Disease Activity Index. 
Table 33 Disease activity as defined by the Paediatric Ulcerative Colitis Activity Index (PUCAI) 
This table shows the severity of disease as defined by PUCAI documented at baseline, 3- and 12-month 
review for data entered to the audit between 12 September 2011 and 29 February 2016. Severity of UC 
classified by PUCAI a score <10 is considered to be remission and >65 is considered to be severe disease. 
PUCAI score Initial treatment 
3-month 
follow-up 
12-month 
follow-up 
Infliximab (Remicade), median (IQR) n=85 55 (35, 70) 
n=36 
13 (5, 38) 
n=8 
5 (0, 15) 
Infliximab biosimilar (Inflectra/Remsima 
combined), median (IQR) 
n=7 
30 (25, 35) n=0 n=0 
IQR = interquartile range; PUCAI = Paediatric Ulcerative Colitis Activity Index. 
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Table 34 Infliximab (Remicade) vs infliximab biosimilars (Inflectra/Remsima) – paediatric 
patients 
This table compares data on paediatric patients treated with either infliximab (Remicade) or its 
biosimilar (Inflectra/Remsima) entered to the audit between 1 March 2015 and 29 February 2016. 
 Infliximab  (Remicade) 
Infliximab biosimilar 
(Inflectra/Remsima) 
General patient characteristics 
Gender: male, % (n/N) 61% (107/175)  60% (49/82) 
Age at diagnosis in years, median (IQR) n=174 12 (10, 14) 
n=79 
12 (10, 14) 
Age at initial treatment in years, median (IQR) n=175 14 (12, 15) 
n=82 
14 (12, 15) 
Time from diagnosis to treatment in years, median 
(IQR) 
n=174 
0.96 (0.42, 2.35) 
n=79 
1.07 (0.47, 2.58) 
Disease severity   
PCDAI at initial treatment, median (IQR) n=42 36 (20, 48) 
n=29 
28 (20, 40) 
PCDAI at 3-month follow-up, median (IQR) n=19 5 (0, 11) 
n=15 
0 (0, 8) 
wPCDAI at initial treatment, median (IQR) n=13 50 (35, 65) 
n=8 
44 (26, 60) 
wPCDAI at 3-month follow-up, median (IQR) n=8 11 (0, 16) 
n=6 
11 (8, 15) 
Response and remission at 3-month follow-up, % (n/N) 
Response to treatment  
(Response is defined as PCDAI decrease of >15) 85% (28/33) 86% (19/22) 
Remission achieved  
(Remission is defined as a PCDAI score of <10) 68% (25/37) 79% (19/24) 
Adverse reactions, % (n/N)   
At initial treatment 2% (3/175) 0% (0/82) 
At 3-month follow-up 5% (4/76) 5% (2/39) 
Concomitant therapy, % (n/N)   
Concomitant therapy for IBD at initial treatment 95% (167/175) 95% (78/82) 
Immunosuppressants  
(includes azathioprine, mercaptopurine and methotrexate) 86% (150/175) 79% (65/82) 
Steroids (includes budesonide, hydrocortisone, 
methylprednisolone and prednisolone) 29% (51/175) 31% (25/82) 
IBD = inflammatory bowel disease; IQR = interquartile range; PCDAI = Paediatric Crohn’s Disease Activity Index; wPCDAI = 
weighted Paediatric Crohn’s Disease Activity Index. 
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Audit objective – appropriateness of prescribing anti-TNFα 
Detailed information about the NICE guidance and recommendations for use of biological therapies in 
patients with IBD in the UK can be found in section 5, pp 47–48 of this report. In Tables 31 and 32, NICE 
criterion 1.5 from technology appraisal 1872 and criterion 1.3 from technology appraisal 3293 have been 
used to assess the appropriateness of prescribing biological therapy.  
 
Table 35 Compliance with NICE technology appraisal 187, criterion 1.5 
This table shows compliance with criterion 1.5 of NICE TA1872 in paediatric patients with CD.  
NICE technology appraisal 187 2016 audit data (1 Mar 2015 – 29 Feb 2016) 
2011 – 2016 audit data 
(12 Sep 2011 – 29 Feb 2016) 
Criterion 1.5 Infliximab may be used for people aged 6–17 years with severe active CD only if (a) the 
disease has not responded to conventional therapy or (b) the person is intolerant of or has 
contraindications to conventional therapy (mercaptopurine, azathioprine, methotrexate, prednisolone, 
budesonide, methylprednisolone or hydrocortisone) 
CD patients with PCDAI score ≥45 
before starting anti-TNFα treatment, 
% (n/N) 
23% (16/71) 17% (74/425) 
CD patients with PCDAI scores who 
were treated with conventional 
therapy at time of or prior to starting 
anti-TNFα treatment, % (n/N) 
96% (68/71) 97% (410/425) 
CD patients who were appropriately 
prescribed anti-TNFα treatment in 
compliance with criterion 1.5 of NICE 
technology appraisal 187, % (n/N) 
20% (14/71) 16% (69/425) 
CD = Crohn’s disease; NICE = National Institute for Health and Care Excellence; PCDAI = Paediatric Crohn’s Disease Activity 
Index; TNFα = tumour necrosis factor alpha. 
 
Table 36 Compliance with NICE technology appraisal 329, criterion 1.3 
This table shows compliance with NICE TA3293 criterion 1.3 in paediatric patients with UC. 
NICE technology appraisal 329 2016 audit data (1 Mar 2015 – 29 Feb 2016) 
2011 – 2016 audit data 
(12 Sep 2011 – 29 Feb 2016) 
Criterion 1.3 Infliximab is recommended for treatment for children and young people aged 6–17 years 
with severe active UC (a) whose disease has responded inadequately to conventional therapy or (b) 
who are intolerant of or have contraindications to conventional therapy (mercaptopurine, azathioprine, 
methotrexate, prednisolone, budesonide, methylprednisolone or hydrocortisone) 
UC patients with PUCAI score ≥65 
before starting anti-TNFα treatment, 
% (n/N)  
27% (7/26) 38% (36/95) 
UC patients with PUCAI scores who 
were treated with conventional 
therapy at time of or prior to starting 
anti-TNFα treatment, % (n/N) 
100% (26/26) 100% (95/95) 
UC patients who were appropriately 
prescribed anti-TNFα therapy in 
compliance with criterion 1.3 of NICE 
technology appraisal 329, % (n/N) 
27% (7/26) 38% (36/95) 
NICE = National Institute for Health and Care Excellence; PUCAI = Paediatric Ulcerative Colitis Activity Index; TNFα = tumour 
necrosis factor alpha; UC = ulcerative colitis. 
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Table 37 Concomitant therapy for IBD – paediatric patients 
This table shows the percentage of all paediatric patients on any immunosuppressant or steroid as 
concomitant therapy during their treatment with biological therapies between 12 September 2011 and 
29 February 2016. 
Type of concomitant therapy 
Treatment time, % (n) 
Initial treatment 3-month follow-up 
CD patients 842 452 
Concomitant therapy for IBD = Yes 93% (780) 90% (405) 
Immunosuppressants* 85% (719) 85% (385) 
Steroids† 22% (187) 12% (52) 
UC patients 149 53 
Concomitant therapy for IBD = Yes 97% (145) 89% (47) 
Immunosuppressants* 70% (104) 77% (41) 
Steroids† 68% (101) 23% (12) 
IBDU patients 59 30 
Concomitant therapy for IBD = Yes 98% (58) 93% (28) 
Immunosuppressants* 76% (45) 73% (22) 
Steroids† 41% (24) 27% (8) 
All IBD 1050 535 
Concomitant therapy for IBD = Yes 94% (983) 90% (480) 
Immunosuppressants* 83% (868) 84% (448) 
Steroids† 30% (312) 14% (72) 
*Immunosuppressants include azathioprine, mercaptopurine and methotrexate.
†Steroids include budesonide, hydrocortisone, methylprednisolone and prednisolone. 
CD = Crohn’s disease; IBD = inflammatory bowel disease; IBDU = inflammatory bowel disease unclassified; UC = ulcerative 
colitis. 
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Audit objective – patient-reported outcome measures 
Outcome measures have traditionally relied on disease activity indexes, but these measures fail to 
assess the patient’s subjective view of their experience. Patient-reported outcome measures (PROMs) 
therefore evaluate quality from the patient’s perspective. Typically, they are short, self-completed 
questionnaires that measure the patient’s health status or health-related quality of life at a single point 
in time. The health status information is collected from patients by way of PROMs questionnaires 
completed before, during and after an intervention (in this case, initiation of biological therapy) and 
provides an indication of the outcomes or quality of care delivered to patients. 
 
IMPACT-III 
IMPACT-III is a health-related quality of life questionnaire for paediatric patients with IBD. The 
questionnaire was originally developed in Canada, but IMPACT-III (UK) has been shown to be a valid tool 
to measure quality of life in children with IBD in the UK.11 It comprises 35 items that address six domains 
of IBD: bowel symptoms, body image, functional / social impairment, emotional impairment, 
tests/treatment and systemic impairment. Total scores range from 35 (poor) to 175 (best), with an 
increase in total score of 10.8 reported to be indicative of a clinically meaningful improvement. 
 
In total, 84 IMPACT-III questionnaires were completed at initial treatment between 1 March 2015 and 
29 February 2016 with a median (IQR) score of 125 (112, 141). At 3-month follow-up, 36 IMPACT-III 
questionnaires were completed, with a median (IQR) score of 143 (129, 153). Very few IMPACT-III 
questionnaires were completed at 12-month follow-up. The limited number of IMPACT-III 
questionnaires completed at initial and follow-up treatment for individual patients means that a median 
change in IMPACT-III score cannot be reliably reported.  
 
Table 38 PROMs questionnaire for paediatric patients (IMPACT-III) 
This table gives completion rates and results of the paediatric quality of life measure used in the 
biological therapies audit – the IMPACT-III questionnaire – for all paediatric patients. 
IBD-PROM 2016 audit data (1 Mar 2015 – 29 Feb 2016) 
2011 – 2016 audit data 
(12 Sep 2011 – 29 Feb 2016) 
Initial treatment 278 1050 
IMPACT-III score, median (IQR) n=84 125 (112, 141) 
n=302 
113 (92, 130) 
3-month follow-up 121 535 
IMPACT-III score, median (IQR) n=36 143 (129, 153) 
n=154 
137 (112, 148) 
12-month follow-up  1 245 
IMPACT-III score, median (IQR) n=0 n=64 144 (130, 153) 
IBD = inflammatory bowel disease; IQR, interquartile range; PROMs = patient-reported outcome measures. 
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IBD-related surgery in paediatric patients 
 
Table 39 IBD-related surgery in paediatric patients with CD 
This table displays the surgical procedures in paediatric patients with CD by type of procedure and 
whether the surgery took place within the 6 months before or after starting biological therapies.  
CD-related surgery 
Paediatric patients with surgery recorded (n=20)* 
Surgery 6 months before 
starting biological therapies  
(n=10) 
Surgery 6 months after starting 
biological therapies  
(n=4) 
Surgical procedure by type (%, n) 
Drainage of abscess 10% (1) - 
Other surgical procedure 40% (4)  25% (1) 
Perianal surgery 30% (3) 25% (1) 
Right hemicolectomy / ileocaecal 
resection 10% (1) 25% (1) 
Small bowel resection - 25% (1) 
Unknown procedure 20% (2) - 
*Patients may have one or more surgeries recorded. 
CD = Crohn’s disease. 
 
Table 40 IBD-related surgery in paediatric patients with UC 
This table displays the surgical procedures in paediatric patients with UC by type of procedure and 
whether the surgery took place within the 6 months before or after starting biological therapies. 
UC-related surgery  
 
Paediatric patients with surgery recorded (n=3) * 
Surgery 6 months before 
starting biological therapies  
(n=1) 
Surgery 6 months after starting 
biological therapies  
(n=1) 
Surgical procedure by type (%, n) 
Colectomy and ileostomy - 100% (1) 
Stoma formation 100% (1) - 
*Patients may have one or more surgeries recorded. 
UC = ulcerative colitis. 
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4: Background information 
 
The burden of inflammatory bowel disease 
The inflammatory bowel diseases UC and CD are lifelong inflammatory conditions that involve the 
gastrointestinal tract. The incidence of IBD has risen dramatically in recent decades and continues to do 
so; it is reported to be as high as 24.3 and 12.7 per 100,000 persons per year in Europe for UC and CD, 
respectively. The reported prevalence in Europe is as high as 505 and 322 per 100,000 persons for UC 
and CD, respectively.12 IBD first presents most commonly in the second and third decades of life, but 
much of the recent increase has been observed in childhood, notably with CD in children increasing 
threefold in 30 years. Between 20% and 30% of patients with UC will require colectomy, and between 
50% and 70% of patients with CD require surgery. The main symptoms of both conditions include 
diarrhoea, abdominal pain, anaemia and an overwhelming sense of fatigue, with, for some patients, 
associated features such as arthritis, anal disease, fistulae, abscesses and skin problems, which can also 
contribute to poor quality of life. In addition, IBD has wide-ranging effects on growth and pubertal 
development, psychological health, education and employment, family life, fertility and pregnancy. 
Effective multidisciplinary care can attenuate relapse, prolong remission, treat complications and 
improve quality of life. 
 
The UK IBD audit 
The UK IBD audit seeks to improve the quality and safety of care for all patients with IBD throughout the 
UK by auditing individual patient care and the provision and organisation of IBD service resources and by 
reporting on inpatient experience and PROMs. The biological therapies audit is one element of the 
wider UK IBD audit. 
 
This report follows the national reports published in 2012, 2013, 2014 and 2015. It builds on the 
previous reports as a continuous audit with increasing rates of participation, and it provides further 
evidence about the safety, efficacy and appropriate use of biological therapies. Furthermore, it enables 
participating sites to benchmark their performance against national data. All data should be considered 
within the context of the actual number of treatments. 
 
Further information on the work of the UK IBD audit project can be accessed via the IBD page of the RCP 
website (www.rcplondon.ac.uk/ibd).  
 
The benefits of the biological therapies audit 
The biological therapies audit is an electronic register of patients receiving treatment and enables IBD 
teams to: 
• monitor the disease activity of patients over the course of their treatment with biological drugs 
• monitor and encourage improved management at patient and service levels, data on adverse 
events, dose escalation and treatment regimens 
• capture the views of patients locally on their quality of life at intervals throughout their treatment 
• benchmark local results against national-level data 
• generate individual patient summaries 
• generate letters detailing treatment plans 
• assess compliance with the IBD standards and NICE quality standard 81.1,4 
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5: What is the role of biological therapy in the treatment of IBD? 
Infliximab (Remicade®) 
Infliximab was first licenced in the EU in 1999 under the brand name Remicade®. It is a chimeric anti-
TNFα monoclonal antibody with potent anti-inflammatory effects that are possibly dependent on 
apoptosis of inflammatory cells. Controlled trials have demonstrated efficacy in both active and 
fistulating CD and UC. Infliximab is typically administered via an intravenous infusion during a hospital 
appointment under the supervision of a suitably qualified health professional. 
Infliximab biosimilar (Inflectra™ and Remsima™) 
Inflectra and Remsima were the first biosimilar monoclonal antibodies to become available in the UK in 
February 2015 after the patent for Remicade® expired. They have been specifically developed to be 
highly similar to their reference medicine Remicade.  
Adalimumab (Humira®) 
Adalimumab (Humira®) was first approved in the EU in 2007. It is a recombinant human immunoglobulin 
(IgG1) monoclonal antibody containing only human peptide sequences. Adalimumab is typically 
delivered via a self-administered injection. Patients are provided with a home supply of the medication 
and, following tuition and close monitoring, are able to manage their own treatment with regular 
medical follow-up. The patent for Humira is due to expire in April 2018 when it is likely that more cost-
effective biosimilar versions will become available. 
Golimumab (Simponi®) 
Simponi contains the active substance golimumab. Simponi is given as a once-monthly 50 mg injection 
under the skin on the same day every month. Golimumab is also a tumour necrosis factor alpha (TNFα) 
inhibitor. 
Vedolizumab (Entyvio®) 
Vedolizumab (Entyvio) is the first approved gut-selective prescription medicine for treatment of 
moderate to severe active CD and UC. Vedolizumab (Entyvio) works by blocking the integration of 
specific integrin receptors with a specific protein. This results in limited migration of circulating 
inflammatory cells across blood vessels and into areas of inflammation in the gastrointestinal tract. It is 
administered by intravenous infusion. 
Approval in the UK 
In multiple technology appraisal 187 for patients with CD2, NICE made the following recommendations: 
• Infliximab and adalimumab may be used within their licensed indications as treatment options
for adults with severe active CD, whose disease has not responded to conventional therapy 
(including immunosuppressive and/or corticosteroid treatments).  
• Infliximab has been recommended for the treatment of active fistulating CD in patients whose
disease has not responded to conventional therapy or who have medical contraindications for 
such therapies. 
• Infliximab is recommended for the treatment of people aged 6–17 years with severe, active CD,
whose disease has not responded to conventional therapy (including corticosteroids, 
immunomodulators and primary nutrition therapy) or who have contraindications to 
conventional therapy. 
• Infliximab and adalimumab should be given as a planned course of treatment until treatment
failure (including the need for surgery) or until 12 months after the start of treatment, 
whichever is shorter. Patients should then be reassessed to determine whether ongoing 
treatment is still clinically appropriate.  
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In multiple technology appraisal 329 for patients with UC3, NICE made the following recommendations: 
• Infliximab (also known as Remicade, Inflectra or Remsima), adalimumab (Humira) and 
golimumab (Simponi) may be used within their licensed indications as treatment for moderate 
to severe active UC in adults whose disease has responded inadequately to conventional 
therapy or who cannot tolerate or who have medical contraindications for such therapies.  
• Infliximab has been recommended for treating severely active UC in children and young people 
aged 6–17 years whose disease has responded inadequately to conventional therapy or who 
cannot tolerate or have medical contraindications for such therapies.  
• Infliximab, adalimumab or golimumab should be given as a planned course of treatment until 
treatment failure (including the need for surgery) or until 12 months after the start of 
treatment, whichever occurs first. Patients should then be reassessed to determine whether 
ongoing treatment is still clinically appropriate. 
 
In technology appraisal 16313, NICE made the following recommendation: 
• Infliximab as an option for the treatment of acute exacerbations of severely active UC only in 
patients for whom ciclosporin is contraindicated or clinically inappropriate.  
 
In technology appraisal 3426, NICE made the following recommendations: 
• Vedolizumab (Entyvio) as an option for the treatment of adults with moderate to severe UC.  
• Vedolizumab is recommended until it stops working, or surgery is required, or for 12 months 
after starting it, whichever is shorter. If the patient is no longer symptomatic treatment can be 
stopped and later restarted if and when symptoms return. 
• Patients who continue to take vedolizumab should be reassessed every 12 months to decide 
whether treatment is still necessary. 
 
In technology appraisal 3527, NICE made the following recommendations: 
• Vedolizumab (Entyvio) as an option for the treatment of adults with moderate to severe CD if a 
TNFα inhibitor has failed (the disease has responded inadequately or loss of response to 
treatment) or a TNFα inhibitor cannot be tolerated or is contraindicated. 
• Vedolizumab is recommended until it stops working, or surgery is required, or for 12 months 
after starting it, whichever is shorter. If the patient is no longer symptomatic treatment can be 
stopped and later restarted if and when symptoms return. 
• Patients who continue to take vedolizumab should be reassessed every 12 months to decide 
whether treatment is still necessary. 
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6: Data entry into the biological therapies audit 
Data entry takes place in the form of ‘submissions’ to a web-based data collection tool. A submission 
refers to data entered in any of the following categories: patient demographics, IBD details, initial 
treatment, follow-up treatment and IBD-related surgery. Once all mandatory fields are completed 
within a category, the data are locked to form a completed submission, and they are then suitable for 
inclusion in national findings. Only locked data can be viewed by the UK IBD audit project team. The full 
audit dataset is available from the RCP website (www.rcplondon.ac.uk/biologics).  
Patient demographics category 
Patients are identified prospectively when the decision to treat using biological therapies is made by a 
clinician. The demographic details of the patient are entered using the web tool; this includes a number 
of patient identifiers that are pseudonymised at the point of data entry and are visible only to the 
participating site. Details of the patient’s consultant and GP can also be entered, although this is not 
mandatory for the audit. 
Disease details category 
This section requires sites to provide details of the patient’s IBD history, including the extent of their 
disease, any related comorbid conditions and details of any surgical procedures undertaken prior to the 
initiation of biological therapies. 
Initial treatment category 
This section collects details of the initial or baseline treatment. The site indicates whether the patient 
has CD, UC or IBDU and which biologic is being used as treatment. The system then generates 
appropriate questions for these options. Information is collected about pre-treatment investigations 
and screening up to the point of completion or abandonment of the treatment, with details of any 
treatment reactions that occur.  
Follow-up treatment category 
Each follow-up treatment that is entered must relate to a previously entered initial treatment 
submission. An unlimited number of follow-up treatments can be completed to allow outgoing data 
collection as the patient continues to be treated with biological therapies. The outcome of each follow-
up treatment – that is, whether treatment will continue or be stopped – must be provided. Details of 
any adverse events are recorded for each follow-up treatment. 
IBD-related surgery category 
Details of IBD-related surgery can be added to the web tool at any time. A prompt to update this section 
of the web tool appears at the conclusion of all initial and follow-up treatment submissions. This allows 
identification of any escalation of treatment that is required while a patient is being treated with 
biological therapy. 
PROMs category 
Data on PROMs are collected at initial treatment and can then be recorded at any additional follow-up. 
For the purpose of the audit, the PROMs completed at 3- and 12-month follow-up treatments are of 
interest.  
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Continued development of the biological therapies audit web tool 
The biological therapies audit web tool has been continually updated and developed in line with the 
requirements identified through feedback from participants and to reflect emerging evidence. Some 
examples of the adaptations made to date are summarised below.  
 
Biosimilars 
To reflect emerging evidence and changing practice, the biological therapies audit was expanded to 
allow auditing of patients who are newly started on biosimilar versions of the biological drugs. 
 
Existing patients 
This was one of the first adaptations of the system and allowed the inclusion of data for patients already 
established on biological therapy in addition to those newly started on these drugs. This allowed sites to 
begin to build their own local registers of patients being treated with biological therapies. This report 
does not contain analyses of data entered for patients already established on biological therapy; data 
for these patients are collected only by those sites that wish to use the data at a local level. 
 
Reporting functions 
Sites can produce patient and treatment summary reports when required; these are summarised briefly 
below. 
Patient summary report  
This is a printable summary of all treatments provided for a specific patient over the course of their 
management; details of any adverse events, acute reactions and relevant surgery are listed. A graphical 
display of the patient’s disease severity scores over time allows a simple visual representation of the 
success/failure of treatment to encourage action when required. The patient summary can be filed in 
the patient’s case notes or provided with an accompanying letter to the patient’s GP. 
Treatment summary report 
This is a printable summary of any isolated initial or follow-up treatment; again, this can be filed in the 
case notes to avoid duplication of effort or included in correspondence with a GP to inform them of the 
treatment provided to their patient on any particular occasion. 
 
Data import function 
The ‘Import data’ function allows users to upload data held in other spreadsheets or registers directly 
into the biological therapy audit web tool through a simple template. This avoids duplication of both 
effort and data entry on sites. 
 
Reduction of mandatory fields 
Following feedback from users regarding the length of time taken to enter submissions onto the web 
tool, the number of mandatory fields is under constant review and is regularly reduced to make the 
process of entering and locking data faster and simpler. 
 
Download function 
Users are able to download their previous site reports, printable versions of the audit tools, help notes 
and a user guide to assist them with data entry.  
 
Data export function 
Users are able to export all data that they have submitted since the start of the audit directly from the 
audit web tool. Data are exported in the form of an editable Excel file. 
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System security of the biological therapies audit web tool 
The document Biological therapies audit system and hosted server security details outlines the system 
security information provided to all sites invited to participate in the audit. It contains details on the 
following topic areas: physical data centre (location, security, admission control, climatisation, electricity 
and fire protection), operating system (version, user access, security, encryption, updates and patches, 
and backups), database software (version, user access and encryption) and application software (source 
control, user access and encryption). It is available to download from the RCP website 
(www.rcplondon.ac.uk/biologics).14 The document gives an overview of the security measures in place, 
while providing assurance that security procedures designed by Microsoft and other industry-standard 
bodies have been followed. The contracted system developer also implemented the recommended 
procedures contained within the NHS document Securing web infrastructure and supporting services 
good practice guideline.15  
The purpose of collecting patient-identifiable data was to make the system useful for staff at a local site 
level by enabling full monitoring and interpretation of the data for the purpose of immediate local 
service improvement and patient care. Patient-identifiable data can be viewed only by registered 
members of the local team, whose access to the site will have been approved via the local clinical lead 
(nearly always a consultant gastroenterologist). Sites using the web tool cannot view data entered at 
other participating sites. The UK IBD audit project team have administrative control to analyse 
anonymised data only and are not able to view any patient-identifiable information.  
In accordance with the principles of the Data Protection Act, sites participating in the biological 
therapies audit are reminded that patients should be informed of the use of their data by means of the 
information leaflets and posters provided by the UK IBD audit project team.
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7: Participation and individual site key indicator data 
Participation  
Since the audit’s inception, levels of participation have varied. Participation falls into one of three main 
categories: 
• Sites that have been entering data, known as participating sites (or participants), which can be
broken down into two further categories: 
- those that have entered data regularly over the past year of data collection 
- those that have previously entered data into the audit but have not done so during the past 
year of data collection 
• Sites that have never entered any data to the audit, known as non-participating sites (or non-
participant). 
• Sites that do not administer biological therapies to their patients with IBD, known as not eligible.
Table 40 Participation status  
The table below shows the different levels of participation for all adult and paediatric registered sites. 
Participation status for registered sites Adult 
sites 
Paediatric 
sites 
Participants with data entry over the past year of data collection 161 27 
Previous participants but no data entered during past year of data collection 37 8 
Non-participant 15 9 
Not eligible 2 0 
Total number of sites 215 44 
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Appendices 
 
Appendix 1: Acronyms used in this report 
 
Anti-TNFα Anti-tumour necrosis factor alpha 
AoMRC Academy of Medical Royal Colleges 
CD Crohn’s disease 
CEEU Clinical Effectiveness and Evaluation Unit 
CUCQ-12 Crohn’s and ulcerative colitis questionnaire 
HBI Harvey–Bradshaw index 
HQIP Healthcare Quality Improvement Partnership 
IBD Inflammatory bowel disease 
IBDU Inflammatory bowel disease unclassified 
IQR Interquartile range 
NCAPOP National Clinical Audit and Patient Outcomes Programme 
NICE National Institute for Health and Care Excellence 
PANTs Personalised Anti-TNF Therapy in Crohn’s disease study 
PCDAI Paediatric Crohn’s Disease Activity Index 
PROMs Patient-reported outcome measures 
RCN Royal College of Nursing 
RCP Royal College of Physicians 
SCCAI Simple Clinical Colitis Activity Index 
UC  Ulcerative colitis 
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Appendix 2: Biological therapy audit governance 
 
Audit governance 
The fifth round of the UK IBD audit is guided by the multidisciplinary IBD programme steering group, 
which is a collaborative partnership between gastroenterologists (the British Society of 
Gastroenterology), colorectal surgeons (the Association of Coloproctology of Great Britain and Ireland), 
patients (Crohn’s and Colitis UK), physicians (the RCP), nurses (the Royal College of Nursing (RCN), 
pharmacists (the Royal Pharmaceutical Society), dietitians (the British Dietetic Association) and 
paediatric gastroenterologists (the British Society of Paediatric Gastroenterology, Hepatology and 
Nutrition).  
 
The audit is commissioned by HQIP as part of the National Clinical Audit and Patient Outcomes 
Programme (NCAPOP). The audit is managed by the Clinical Effectiveness and Evaluation Unit of the 
RCP. Each hospital identified an overall clinical lead who was responsible for data collection and entry 
for their IBD service. Data were collected by hospitals using a standardised method.  
 
Any enquiries in relation to the work of the UK IBD audit can be directed to ibd.audit@rcplondon.ac.uk. 
 
IBD programme steering group members 
The names of members of the biological therapy audit subgroup are shown in bold. This is the group of 
people tasked with leading this particular element of the UK IBD audit and who contributed 
considerably to the development of this element of work. 
 
Association of Coloproctology of Great Britain and Ireland  
Mr Omar Faiz, consultant colorectal surgeon, St Mark’s Hospital, Harrow 
Mr Graeme Wilson, consultant colorectal surgeon, Western General Hospital, Edinburgh (until 
March 2016) 
British Dietetic Association  
Ms Katie Keetarut, senior IBD dietitian, University College Hospital, London (until March 2016) 
British Society of Gastroenterology 
Dr Ian Arnott, IBD programme clinical director, chair of the UK IBD audit steering group; consultant 
gastroenterologist, Western General Hospital, Edinburgh 
Dr Stuart Bloom, consultant gastroenterologist, University College Hospital, London 
Dr Keith Bodger, consultant physician and gastroenterologist, University Hospital Aintree, Liverpool 
Dr Fraser Cummings, consultant gastroenterologist, University Hospital Southampton 
Professor Chris Probert, consultant gastroenterologist, Royal Liverpool University Hospital (until 
March 2016) 
Dr Ian Shaw, IBD programme associate director; consultant gastroenterologist, Gloucestershire 
Royal Hospital 
Dr Graham Turner, consultant gastroenterologist, Royal Victoria Hospital, Belfast (until March 2016) 
Professor John Williams, consultant gastroenterologist, Abertawe Bro Morgannwg University 
Health Board; director, Health Informatics Unit, RCP (until March 2016) 
British Society of Paediatric Gastroenterology, Hepatology and Nutrition 
Dr Charles Charlton, consultant paediatric gastroenterologist, Queens Medical Centre, Nottingham 
(until March 2016) 
Dr Sally Mitton, consultant paediatric gastroenterologist, St George’s Hospital, London (until March 
2016) 
Dr Richard K Russell, consultant paediatric gastroenterologist, Royal Hospital for Children, Glasgow 
Crohn’s and Colitis UK (NACC) 
Mr David Barker, chief executive 
Ms Jackie Glatter, health service development adviser (until March 2016) 
Revd Ian Johnston, patient representative (until March 2016) 
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Primary Care Society for Gastroenterology 
Dr Jamie Dalrymple, GP partner, Drayton and St Faiths medical practice (until March 2016) 
Royal College of Nursing 
Ms Kay Crook, paediatric gastroenterology clinical nurse specialist, St Mark’s Hospital, Harrow 
Ms Diane Hall, clinical nurse specialist, Heartlands Hospital, Birmingham (until March 2016) 
Dr Karen Kemp, IBD clinical nurse specialist, Manchester Royal Infirmary 
Royal College of Physicians 
Ms Rhona Buckingham, operations director, CEEU 
Ms Kajal Mortier, project manager, UK IBD programme 
Ms Susan Murray, programme manager, UK IBD programme  
Ms Aimee Protheroe, programme development manager, UK IBD programme 
Dr Kevin Stewart, clinical director, CEEU 
Royal Pharmaceutical Society of Great Britain 
Ms Anja St Clair-Jones, consultant pharmacist gastroenterology, Royal Sussex County Hospital, 
Brighton 
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Appendix 3: Consort diagram of follow-up at 3 months for adult patients 
 
Fig 4 Consort diagram for follow-up treatment at 3 months of adult patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD = Crohn’s disease; IBDU = inflammatory bowel disease unclassified; PANTs = Personalised Anti-TNF Therapy in Crohn’s 
disease study; UC = ulcerative colitis. 
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Appendix 4: Consort diagram of follow-up at 3 months for paediatric patients 
 
Fig 5 Consort diagram for follow-up treatment at 3 months for paediatric patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD = Crohn’s disease; IBDU = inflammatory bowel disease unclassified; PANTs = Personalised Anti-TNF Therapy in Crohn’s 
disease study; UC = ulcerative colitis. 
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Appendix 5: Full national audit results – adult services 
Appendix 5 can be found online at: www.rcplondon.ac.uk/biologics. 
 
Appendix 6: Full national audit results – paediatric services 
Appendix 6 can be found online at: www.rcplondon.ac.uk/biologics. 
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